1533 related articles for article (PubMed ID: 30791945)
1. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease.
Nordengen K; Kirsebom BE; Richter G; Pålhaugen L; Gísladóttir B; Siafarikas N; Nakling A; Rongve A; Bråthen G; Grøntvedt GR; Gonzalez F; Waterloo K; Sharma K; Karikari T; Vromen EM; Tijms BM; Visser PJ; Selnes P; Kramberger MG; Winblad B; Blennow K; Fladby T
J Neuroinflammation; 2023 Dec; 20(1):298. PubMed ID: 38093257
[TBL] [Abstract][Full Text] [Related]
3. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
[TBL] [Abstract][Full Text] [Related]
4. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.
Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL
Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
[TBL] [Abstract][Full Text] [Related]
8. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal Fluid and Blood CX3CL1 as a Potential Biomarker in Early Diagnosis and Prognosis of Dementia.
Kulczyńska-Przybik A; Słowik A; Mroczko P; Borawski B; Groblewska M; Borawska R; Mroczko B
Curr Alzheimer Res; 2020; 17(8):709-721. PubMed ID: 33167838
[TBL] [Abstract][Full Text] [Related]
10. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
[TBL] [Abstract][Full Text] [Related]
12. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
[TBL] [Abstract][Full Text] [Related]
13. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
Li TR; Lyu DY; Liu FQ;
J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
16. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
18. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
19. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
[TBL] [Abstract][Full Text] [Related]
20. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
